Phase 3 N=270 Evaluation of an Investigational Multi-Purpose Solution (MPS)
Study Focus is Healthy Contact Lens Wearers
Primary: Mean Lens Cleanliness as Measured by Light Reflectance — 65.5; 66.8 light reflectance score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=278 A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
Hypertension
Primary: Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension)…
Phase 3 N=400 Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
Schizophrenia · Schizophrenic Disorders · Psychotic Disorders
Primary: The Number of Participants Who Experienced Adverse Events as a Measure of Safety and Tolerability — 32; 88; 221; 341 Number of Participants
Phase 3 N=646 Abatacept Versus Adalimumab Head-to-Head
Rheumatoid Arthritis
Primary: The Proportion of Participants Meeting the American College of Rheumatology (ACR) Criteria of 20% Improvement (ACR20) After 12 Months of Treatment - Intent to Treat…
Phase 3 N=463 Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Colorectal Cancer · Metastases
Primary: Progression-free Survival Time — 8.0; 7.3 weeks — p=<0.0001
Phase 3 N=154 Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)
Surgical Procedures, Elective
Primary: Incidence of Residual Neuromuscular Blockade (NMB) as Defined by a Train-of-Four (TOF) Ratio <0.9 at Post Anesthesia Care Unit (PACU) Entry — 0; 33 participants…
Phase 3 N=58 Biofeedback-Based Cognitive Behavioral Treatment for Temporomandibular Disorders
Temporomandibular Disorders
Primary: Pain Intensity (German Pain Questionnaire; Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD)) — 5.40; 5.53; 3.90; 3.89 units on a scale
Phase 3 N=190 3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
Post-menopausal Osteoporosis
Primary: Percentage Change in Total Hip Bone Mineral Density BMD at Year 6 (Baseline) and Year 9 — -0.54; -1.31 Percentage Change of BMD
Phase 3 N=36 Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C
Genotype 1 Chronic Hepatitis C
Primary: Number of Participants With Extended Rapid Virologic Response (eRVR) — 13; 18 Participants
Phase 3 N=250 Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
Herpes Zoster · Shingles
Primary: The Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody at 6 Weeks Postvaccination — 149.8; 410.8 gpELISA units/mL
Phase 3 N=290 Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis
Tinea Pedis
Primary: Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2) — 73; 10 participants
Phase 3 N=371 BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
Colon Cancer
Primary: Efficacy - Preparation Quality Using a 4 Point Scale — 94; 94 percentage of participants
Phase 3 N=218 Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Type 2 Diabetes Mellitus · High HbA1c Level · Inadequate Glycaemic Control
Primary: Adjusted Mean Change From Baseline in HbA1c Levels — -0.17; -0.86 Percent — p=<0.0001
Phase 3 N=250 A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Osteoporosis, Postmenopausal
Primary: Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6 — 4.26; 1.20 percent change — p=<0.0001
Phase 3 N=573 Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Abscess · Wound Infection · Surgical Site Infection
Primary: Early Clinical Efficacy — 240; 233; 48; 52 participants